Foghorn Therapeutics Inc.
FHTXNasdaq
$5.19
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↓ -11.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$360.9M
Enterprise Value
$273.2M
P/E
—
P/S
12.8
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-24.2%
Dividend Yield
—
Revenue (TTM)
$28.2M
Net Income (TTM)
-$75.3M
Free Cash Flow (TTM)
-$87.4M
Gross Margin
—
Operating Margin
-301.3%
Net Margin
-266.9%
ROE
98.6%
ROIC
—
Debt / Equity
—
Net Cash
$87.7M
Return 1Y
-14.9%
Company profile
Foghorn Therapeutics Inc. is developing a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also developing an enzyme inhibitor and protein degrader as selective modulators of BRM.
- CEO
- Adrian Gottschalk
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- Massachusetts
- Website
- foghorntx.com
Management & directors
- Gottschalk AdrianChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
FHTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.3M↓ -45.1%
Diluted EPS-$0.29↓ -3.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $430,000.00 | $1.3M | $19.2M | $34.2M | $22.6M | $30.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$68.5M | -$100.7M | -$117.1M | -$107.9M | -$102.7M | -$86.4M |
| Net income | -$68.8M | -$101.3M | -$108.9M | -$98.4M | -$86.6M | -$74.3M |
| Diluted EPS | -$6.23 | -$2.73 | -$2.62 | -$2.34 | -$1.58 | -$1.18 |
| Operating cash flow | -$31.3M | -$50.3M | $193.6M | -$118.1M | -$100.4M | -$86.1M |
| Free cash flow | -$47.5M | -$53.6M | $192.4M | -$119.3M | -$101.3M | -$86.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -15937.4% | -7637.1% | -609.2% | -315.9% | -454.3% | -279.5% |
| Net margin | -16000.0% | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $7.8M | $2.9M | $6.0M | $7.6M | $8.2M | $9.2M | $3.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$26.6M | -$23.9M | -$24.0M | -$22.9M | -$21.1M | -$18.5M | -$23.9M | -$21.6M |
| Net income | -$23.0M | -$19.1M | -$19.5M | -$18.8M | -$17.9M | -$15.8M | -$21.7M | -$19.9M |
| Diluted EPS | -$0.45 | -$0.31 | -$0.23 | -$0.30 | -$0.28 | -$0.25 | -$0.35 | -$0.29 |
| Operating cash flow | -$25.5M | -$21.0M | -$24.5M | -$24.0M | -$21.0M | -$18.9M | -$22.3M | -$25.3M |
| Free cash flow | -$25.6M | -$21.3M | -$25.0M | -$24.0M | -$21.0M | -$18.9M | -$22.3M | -$25.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -386.6% | -305.5% | -840.5% | -385.0% | -279.2% | -226.9% | -258.2% | -660.3% |
| Net margin | -333.6% | -244.9% | -682.9% | -316.4% | -237.3% | -194.4% | -234.3% | -608.4% |
Company news
May 12, 2026
May 7, 2026
- 74d agoCorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Releasefinance.yahoo.com
- 74d agoFoghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com
- 74d agoFoghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Updatefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-10 | GOTTSCHALK ADRIAN· Chief Executive Officer | Gift | 59,208 | $0.00 | $0.00 | filing |
| 2026-04-10 | GOTTSCHALK ADRIAN· Chief Executive Officer | Gift | 59,208 | $0.00 | $0.00 | filing |
| 2026-04-09 | GOTTSCHALK ADRIAN· Chief Executive Officer | Gift | 47,497 | $0.00 | $0.00 | filing |
| 2026-04-09 | GOTTSCHALK ADRIAN· Chief Executive Officer | Gift | 47,497 | $0.00 | $0.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.